Subscribe

Heart Tronics, Inc. (HRTT)

USD0.00 +0.00 (+0.00%)
US OTC Healthcare Medical - Devices
Address 4705 Laurel Canyon Boulevard 91607
Studio City, CA, US
CEO Budimir S. Drakulic
IPO 1999-10-27
ISIN US42234M1018

Explore sections of this company profile

Description

Heart Tronics, Inc., established in 1987 and headquartered in Studio City, California, is a medical technology company specializing in the research, development, and marketing of medical devices across the United States. These devices are designed to track and quantify biological signals, aiding in the identification of illnesses that affect an individual's well-being. Among its current offerings is the Fidelity 100 Monitor System, an integrated solution where its Model 100 Patient Module gathers, processes, and enhances electrocardiogram (ECG) data from a patient via ten electrodes, transmitting this information wirelessly to a laptop computer. Currently in development are several innovative products. The Fidelity 350 Holter Monitor is a portable device crafted to collect continuous ECG data for conditions like arrhythmia and fleeting heart diseases, allowing patients to maintain their normal routines outside of clinical settings. Another developmental product is the Fidelity 200 Event Recording System/Heart Tempo Card, an over-the-counter heart monitoring device intended for proactive detection by individuals who wish to keep an eye on their cardiac health. The company also produces the Cardiac Vest, a snug-fitting, flexible vest or undergarment where electrodes are integrated directly into the fabric. Additionally, the Fidelity 400 Intracardiac Monitor utilizes Heart Tronics' unique signal acquisition and amplification technology to interpret intracardiac signals obtained from a catheter inserted within the heart. The company, formerly known as Signalife, Inc., rebranded as Heart Tronics, Inc. in November 2008.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
USD0.00 +0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
206
Beta
-0.07
Float Shares
72.9K
Free Float %
91.7%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.00% +0.00% +0.00% +0.00% +0.00% +0.00% +0.00% +0.00% -30.00% -99.19% -100.00%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
0.00
Ratings Trend (MoM)
Rating 2024-11 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
-38.21
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Operational MOAT
✗ Below peers
  • Revenue growth Medical - Devices: +11.2%
    -100.0%
  • EPS growth Medical - Devices: +28.5%
    -8.4% Q3'08: -93.7% (vs Q3'07)
  • FCF margin FCF growth · Medical - Devices: +30.9%
  • EBIT margin Medical - Devices: +6.2%
  • ROIC Medical - Devices: +3.3%
    -461.7% Q3'08: -1,193.1% (vs Q3'07)
  • Share dilution Medical - Devices: 0.0%
    +21.9% Q3'08: +40.4% (vs Q3'07)
  • Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×
    -0.01× Q3'08: 0.02× (vs Q3'07)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
WACC components (optional)
Ke (Cost of Equity) = Rf + β (-1.49) × ERP
WACC = 0% × Ke + 100% × Kd (4.3%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
Current price: 0.00
Enterprise Value: Equity Value: Terminal Value: TV as % of EV:

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2008
actual
Dec 2009
actual
Revenue
est.
1.62M
est.
EBITDA
est.
972.0K
est.
EBIT
est.
972.0K
est.
Net Income
est.
est.
SGA
est.
5.89M
est.
EPS
est.
est.

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-3.51M
OE per share TTM
-274.49
Owner's Yield
-32,406,005.54%
Maintenance CapEx ratio
Maint CapEx / Avg PPE
575.0%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
Total invested
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
Shares Outstanding
79.6K

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Budimir S. Drakulic Chief Scientist, Vice President and Director of Research & Development 233.0K
Rowland Perkins Chief Administrative Officer and Director 18.0K male
Claire Mouton LaFrance Director of Marketing and Communications female
James J. Mazeika Director of Business Development male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings reports

Stock splits